Total
0
Shares
Immutep (ASX:IMM) - CEO, Marc Voigt (left)
CEO, Marc Voigt (left)
Source: ShareCafe
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotechnology company Immutep (IMM) has expanded Part B of its TACTI-002 phase two trial, following a preliminary safety and efficacy review
  • The study is evaluating a combination of Immutep’s lead product candidate, efti, with MSD’s KEYTRUDA in patients with head, neck and lung cancers
  • Following the review and recommendation by the data monitoring committee, Immutep has begun recruiting an additional 13 second-line non-small cell lung cancer patients to form stage two of Part B
  • The trial is being conducted at 12 centres in Australia, Europe, the U.K. and the U.S.
  • Shares last traded at 31.5 cents

Immutep (IMM) has expanded Part B of its TACTI-002 phase two trial, following a recommendation from the data monitoring committee.

The biotechnology company will recruit an additional 13 patients with second-line non-small cell lung cancer (NSCLC) to form stage two of Part B.

It comes after a preliminary safety and efficacy review of stage one of Part B by the data monitoring committee.

The study is being conducted in collaboration with MSD, testing the efficacy of a combined treatment in patients with second line head and neck squamous cell carcinoma or NSCLC in first and second line.

Immutep’s lead product candidate eftilagimod alpha, or simply efti, is being trialled with MSD’s KEYTRUDA, or pembrolizumab.

The trial is being conducted at 12 centres in Europe, the U.K., the U.S. and Australia.

Part A enrolled patients with NSCLC and PD-X naive, Part B enrolled second-line NSCLC and PD-X refectory patients, and Part C will recruit second-line head and neck squamous cell carcinoma and PD-X naive patients.

Shares last traded at 31.5 cents.

IMM by the numbers
More From The Market Herald
Advanced Human Imaging, AHI- CEO and Co-Founder Vlado Bosanac

" Advanced Human Imaging (ASX:AHI) appoints Edward F. Greissing Jr. to board

Advanced Human Imaging (AHI) has appointed Edward F. Greissing Jr. to board effective from November 30, 2021.
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert

" Rhythm Biosciences (ASX:RHY) achieves CE Mark for ColoSTAT

Cancer diagnostic technology company Rhythm Biosciences (RHY) has achieved CE Mark certification for ColoSTAT.
EMVision Medical Devices (ASX:EMV) - CEO, Ron Weinberger

" EMVision Medical Devices (ASX:EMV) reports more strong results

Medical device maker EMVision (EMV) is spiking on the ASX today after releasing further results from a pilot clinical trial of its brain
ECS Botanics (ASX:ECS) - Managing Director and Founder, Alex Keach

" ECS Botanics’ (ASX:ECS) subsidiary buds $4.9m supply agreement

ECS Botanics’ (ECS) subsidiary has secured a $4.9 million agreement to supply resin to Australian cannabis company, Cannvalate.